Germany wants to buy Sputnik COVID vaccine if approved by EU, source says By Reuters

0
23

© Reuters. FILE PHOTO: File labelled “Sputnik V coronavirus disease (COVID-19) vaccine

BERLIN (Reuters) – Germany is about to start bilateral negotiations with Russia to obtain its Sputnik V COVID-19 vaccine, a source told Reuters on Wednesday, adding that any final agreement depended on Russia providing key data to the European Medicines Agency (EMA).

The European Commission told health ministers of EU member states on Wednesday that Brussels was not planning to start talks with Russia on a preliminary contract for Sputnik V as it did with other vaccine providers, a person with knowledge of the matter told Reuters on condition of anonymity.

That is why German Health Minister Jens Spahn announced during the virtual meeting that Germany would start preliminary negotiations with Russia on a bilateral agreement to secure the vaccine, the source added.

In the preliminary talks, Germany first wants to determine which quantities Russia can deliver and when, the source said.

In any case, Germany will only buy the Russian vaccine once it has been approved by EMA and for this it is paramount that Russia provides the necessary data, the source added.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.